Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA
July 13, 2023 08:00 ET
|
Akari Therapeutics Plc
Akari is on track for start of enrollment by the end of 2023 in the registrational Phase 3 study of nomacopan in pediatric HSCT-TMAAkari is moving forward into a Phase 3 double-blind...
Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy
July 11, 2023 08:00 ET
|
Akari Therapeutics Plc
Akari has completed evaluation of long-acting PAS-nomacopan candidates and selected a single drug candidate to move forward into clinical trials for treatment of geographic atrophy (GA)The company...
Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation
July 06, 2023 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, July 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors
July 05, 2023 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics to Participate in A.G.P.’s Virtual Healthcare Conference
May 16, 2023 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights
May 01, 2023 08:00 ET
|
Akari Therapeutics Plc
Development of lead asset nomacopan, a novel dual-mechanism inhibitor of complement C5 and leukotriene B4 (LTB4), is focused on two priority pipeline programs with potential to transform the...
Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement
April 25, 2023 16:15 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs
April 14, 2023 08:00 ET
|
Akari Therapeutics Plc
Event on May 22nd will feature Elias Reichel, M.D., Professor, Department of Ophthalmology, Tufts University School of Medicine NEW YORK and LONDON, April 14, 2023 (GLOBE NEWSWIRE) -- Akari...
Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology
April 11, 2023 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, April 11, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting
April 03, 2023 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, April 03, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...